Greenwich LifeSciences (NASDAQ:GLSI) Issues Earnings Results

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.40), Zacks reports.

Greenwich LifeSciences Trading Up 1.2 %

GLSI stock traded up $0.11 during midday trading on Friday, reaching $8.95. The stock had a trading volume of 71,770 shares, compared to its average volume of 43,889. Greenwich LifeSciences has a 52-week low of $8.06 and a 52-week high of $18.75. The company's fifty day simple moving average is $10.87 and its 200 day simple moving average is $12.37. The company has a market cap of $118.80 million, a price-to-earnings ratio of -11.19 and a beta of 1.76.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "buy" rating and set a $38.00 target price on shares of Greenwich LifeSciences in a research note on Tuesday, February 11th.

Insider Activity

In other news, CEO Snehal Patel purchased 5,500 shares of the stock in a transaction dated Friday, April 4th. The shares were purchased at an average price of $8.73 per share, with a total value of $48,015.00. Following the transaction, the chief executive officer now owns 5,558,002 shares in the company, valued at $48,521,357.46. The trade was a 0.10 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 51.67% of the company's stock.

Institutional Trading of Greenwich LifeSciences

A hedge fund recently raised its stake in Greenwich LifeSciences stock. Bank of America Corp DE grew its stake in Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) by 22.3% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 7,262 shares of the company's stock after buying an additional 1,322 shares during the quarter. Bank of America Corp DE owned 0.06% of Greenwich LifeSciences worth $82,000 as of its most recent filing with the SEC. Institutional investors own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.